Overview

Treating Hyperexcitability in AD With Levetiracetam

Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore the relationship between cortical hyperexcitability, abnormalities of brain network function, and cognitive dysfunction in human patients with AD and whether administration of the antiepileptic medication levetiracetam (LEV) normalizes these measures and improves cognition.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Treatments:
Levetiracetam